|
西陵区新冠血清抗体水平监测结果分析
|
Abstract:
目的:了解西陵区新冠病毒人群抗体水平变化情况,提前做好防疫物资和医疗资源的准备工作,最大程度保护人民群众生命安全和身体健康,最大限度减少疫情对经济社会发展的影响。方法:采用描述性流行病学方法,对西陵区本地人群新冠血清抗体监测资料进行统计分析。结果:西陵区11月(第四轮)本地人群IgG滴度水平中位数为265.17 AU/mL,较7月(第三轮)同人群IgG滴度水平(302.79 AU/mL)、4月(第二轮)同人群IgG滴度水平(302.60 AU/mL)和3月(第一轮)同人群IgG滴度水平(320.67 AU/mL)均显著下降(P < 0.05)。结论:西陵区本地人群IgG滴度水平仍处于较高水平,免疫屏障已经建立,且药物和医疗的可及性较之前更好,后续应对可能出现的感染波峰,发生医疗资源挤兑的可能性较低。
Objective: To understand the change of antibody level of COVID-19 population in Xiling District, prepare epidemic prevention materials and medical resources in advance, protect people’s life safety and health to the greatest extent, and minimize the impact of the epidemic on economic and social development. Methods: Descriptive epidemiological methods were used to statistically analyze the monitoring data of COVID-19 serum antibody in local population in Xiling District. Results: The median IgG titer level of the local population in Xiling District in November (fourth round) was 265.17 AU/mL, which was significantly lower than the IgG titer levels of the same population in July (third round) (302.79 AU/mL), April (second round) (302.60 AU/mL), and March (first round) (320.67 AU/mL) (P < 0.05). Conclusion: The IgG titer level of the local population in Xiling District is still at a high level, the immune barrier has been established, and the accessibility of drugs and medical care is better than before. It is less likely that there will be a medical resource crunch in response to possible infection peaks in the future.
[1] | 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml, 2022-10-01. |
[2] | Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/s0140-6736(20)30183-5 |
[3] | 宋雅婷, 侯欣, 陆旻雅, 等. 新型冠状病毒血清特异性抗体检测技术应用探讨[J]. 协和医学杂志, 2020, 11(6): 649-653. |
[4] | 黄悦, 庄春兰, 葛胜祥, 等. 2019年新型冠状病毒血清学检测的临床和公共卫生意义探讨[J]. 病毒学报, 2020, 36(3): 537-540. |
[5] | 貌盼勇, 朱雷, 王佑春, 等. SARS-CoV特异性抗体产生规律的初步研究[J]. 中华流行病学杂志, 2004, 25(10): 856-858. |
[6] | Castro Dopico, X., Ols, S., Loré, K. and Karlsson Hedestam, G.B. (2021) Immunity to SARS-CoV-2 Induced by Infection or Vaccination. Journal of Internal Medicine, 291, 32-50. https://doi.org/10.1111/joim.13372 |
[7] | Vadrevu, K.M., Ganneru, B., Reddy, S., Jogdand, H., Raju, D., Sapkal, G., et al. (2022) Persistence of Immunity and Impact of Third Dose of Inactivated COVID-19 Vaccine against Emerging Variants. Scientific Reports, 12, Article No. 12038. https://doi.org/10.1038/s41598-022-16097-3 |
[8] | Abufares, H.I., Oyoun Alsoud, L., Alqudah, M.A.Y., Shara, M., Soares, N.C., Alzoubi, K.H., et al. (2022) COVID-19 Vaccines, Effectiveness, and Immune Responses. International Journal of Molecular Sciences, 23, Article 15415. https://doi.org/10.3390/ijms232315415 |
[9] | Takahashi, T. and Iwasaki, A. (2021) Sex differences in immune responses. Science, 371, 347-348. https://doi.org/10.1126/science.abe7199 |
[10] | 张蕊, 燕忠生, 牛小娟. “乙类乙管”疫情防控政策下甘肃省兰州市中青年人群新冠病毒感染的流行学调查及思考[J]. 中国呼吸与危重监护杂志, 2023, 22(7): 480-485. |
[11] | 中华人民共和国国家卫生健康委员会. 新型冠状病毒感染的肺炎纳入法定传染病管理的公告[EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/44a3b8245e8049d2837a4f27529cd386.shtml, 2022-04-20. |
[12] | 湖北省人民政府. 湖北省人民政府关于加强新型冠状病毒感染的肺炎防控工作的通告[EB/OL]. https://www.hubei.gov.cn/zfwj/ezf/202002/t20200220_2142431.shtml, 2022-04-20. |
[13] | 丁哲渊, 吴昊澄, 吴晨, 等. 浙江省新型冠状病毒肺炎疫情应急响应期间其他法定传染病监测分析[J]. 疾病监测, 2020, 35(8): 746-752. |
[14] | 国家卫生健康委员会. 《关于对新型冠状病毒感染实施“乙类乙管”的总体方案》解读问答[J]. 中国新闻发布(实务版), 2023(1): 21-24. |